Trial Profile
Efficacy and safety trial of AJG555 in patients with chronic constipation (Phase 3 study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs AJG 555 (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Ajinomoto Pharma; EA Pharma
- 21 Sep 2018 According to an EA Pharma media release, the company has obtained the marketing and manufacturing approval of chronic constipation treatment MOVICOL (AJG-555). Data from the trial supported the approval.
- 05 Oct 2017 Status changed from active, no longer recruiting to completed.
- 02 Sep 2016 Status changed from recruiting to active, no longer recruiting.